Effects of Berberine Hydrochloride and Bifidobacterium in Prediabetes Prevention and Treatment

Last updated: November 11, 2018
Sponsor: Xijing Hospital
Overall Status: Trial Not Available

Phase

2/3

Condition

Diabetes Mellitus, Type 2

Diabetes And Hypertension

Diabetes (Pediatric)

Treatment

N/A

Clinical Study ID

NCT02082756
2013KTZB03-02-01B
  • Ages 18-70
  • All Genders

Study Summary

The aim of this study is to assess the beneficial effects of Bifidobacterium and Berberine Hydrochloride on lowering glucose and delaying progress to diabetes in patients with prediabetes and to detect the potential mechanism.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Informed consent obtained before any trial-related activities

  • Male or female between 18 and 70 years of age

  • 19≤Body mass index(BMI)≤30kg/m2

  • No participate in any clinical trial at least 3 months

  • Fasting blood glucose(FBG)<7.0mmol/L and 2-hour postprandial bloodglucose(2hPBG)<11.1mmol/L

  • Females in child-bearing period should be given birth control

  • No severe disease about heart, lung and kidney

  • Ability and willingness to adhere to the protocol including performance ofself-monitored blood glucose (SMBG) profiles according to the protocol;

  • Subject is likely to comply with the Investigators instruction.

Exclusion

Exclusion Criteria:

  • Type 2 diabetes mellitus or type 1 diabetes mellitus

  • Females of childbearing potential who are pregnant,breastfeeding or intend to becomepregnant or are not using adequate contraceptive methods

  • Impaired liver function, defined as Aspartate aminotransferase(AST) or Alaninetransaminase(ALT)> 2 times upper limit of normal (central laboratory)

  • Impaired renal function, defined as serum-creatinine≥133μmol/L

  • Uncontrolled treated/untreated severe hypertension (systolic blood pressure≥160mmHgand /or diastolic blood pressure≥95mmHg)

  • Chronic gastrointestinal diseases

  • Cancer and medical history of cancer (except basal cell skin cancer or squamous cellskin cancer)

  • Any clinically significant disease or disorder, which in the Investigator's opinioncould interfere with the results of the trial

  • Mental incapacity, psychiatric disorder, unwillingness or language barriers precludingadequate understanding or co-operation, including subjects not able to read and write

  • Previous participation in this trial. Participation is defined as randomized.Re-screening of screening failures is allowed only once within the limits of therecruitment period

  • Known or suspected hypersensitivity to trial products or related products

  • Known or suspected abuse of alcohol, narcotics or illicit drugs.

Study Design

Study Start date:
November 01, 2015
Estimated Completion Date:
April 30, 2018

Study Description

Gut microbiota may play an important role in patients with prediabetes. Berberine, which is usually used as an antibiotic drug, has been reported a potential glucose-lowering effect in vitro and in vivo studies. Bifidobacterium, as a familiar probiotics, can modulate gut microbiota and improve glucose and lipid metabolism in animal experiments. Therefore, the aim of this study is to assess the beneficial effects of Bifidobacterium and Berberine Hydrochloride on lowering glucose and delaying progress to diabetes in patients with prediabetes and to detect the potential mechanism.

Connect with a study center

  • Second Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shaanxi 710004
    China

    Site Not Available

  • Shaanxi Provincial People's Hospital

    Xi'an, Shaanxi 710068
    China

    Site Not Available

  • The 323rd Hospital of People's Liberation Army

    Xi'an, Shaanxi 710054
    China

    Site Not Available

  • First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an,, Shaanxi 710061
    China

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.